A Phase II Study for Prostate Cancer Monitoring Using 18FDCFPyL and Blood Based Biomarkers
Study of Prostate Cancer Monitoring Using PyL and Blood-Based Biomarkers
Sponsor: Emerson Lim, MD
Enrolling: Male Patients Only
IRB Number: AAAR6032
U.S. Govt. ID: NCT03585114
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: You are being asked to participate in this research study because you have been diagnosed with metastatic castrate resistant prostate cancer (mCRPC) and are scheduled to start a new treatment. The purpose of this study is to see if changes in 18FDCFPyL (PyL) PET/CT scans before starting your new treatment and after 6 weeks on treatment is associated with stability of your disease. We will also see if changes in prostate cancer tumor DNA (ctDNA) and cell particles (exosomes) in the blood is associated with stability of your disease. We hope that this may one day lead to better tests to evaluate patients with prostate cancer.
This study is closed
Mark Stein, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with prostate cancer? Yes No
Are you able and willing to sign an informed consent form? Yes No
Are you willing to comply with clinical trial instructions? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator